The potent and selective inhibitors of BRAF‐mutant kinase vemurafenib (V), dabrafenib (D), and encorafenib (E) have demonstrated an advantage in survival outcomes in untreated BRAFv600 mutant metastatic melanoma (MM) compared with standard chemotherapy (Chapman et al. 2017, 2011). The gene discussed is BRAF; the disease is Miyoshi myopathy.